*** Consensus New Buys :- Perrigo (PRGO) : In the second quarter, Farallon Capital, Perry Capital, Lone Pine Capital, and Third Point all established new stakes in PRGO. This name attracted a few funds that focus on event-driven plays given that it received a takeover offer from Mylan (MYL). John Paulson’s firm owns shares of MYL and just recently said he’d vote in favor of the merger, per a statement. The whole situation has been a bit of a merger circus. Teva Pharmaceutical (TEVA) originally tried to acquire MYL. MYL then rejected those advances and went out to acquire PRGO in order to fend off TEVA. Meanwhile, TEVA recently purchased Allergan’s (AGN) generics business.
- Broadcom (BRCM): This is yet another risk arbitrage related play. During the quarter, Paulson & Co, Coatue, and Farallon all built new stakes in BRCM as it received a takeover offer from Avago Technologies (AVGO).
- Starwood Hotels (HOT): Are you seeing a theme yet? While there’s been nothing official announced, rumors have persisted that the company is an ideal target for a sale or merger. Names such as Intercontinental Hotels Group (IHG) and Wyndham (WYN) have been floated by the media as potential partners. During Q2, Omega Advisors, Third Point, and Paulson & Co all built new stakes in HOT. Shares are also now trading lower than at any point where these funds could have bought during Q2.
- T-Mobile (TMUS): Farallon, Coatue, and Third Point were among those starting new positions in TMUS during the second quarter. Rogue CEO John Legere has shaken up the wireless industry and has seen his company gaining market share against incumbents AT&T (T), Verizon (VZ), and Sprint (S). Per media reports, TMUS had also been rumored to be in merger talks with Dish Network (DISH), though nothing has come to fruition on that front thus far.
- Williams (WMB): JANA Partners, Farallon, and Third Point accumulated shares of WMB during Q2. WMB is an energy infrastructure company that focuses on natural gas, natural gas liquids, and olefins.
*** Consensus Increased Positions :
- Google (GOOGL): Coatue, Farallon, Glenview Capital, and Viking Global all increased exposure to this search engine giant in Q2. The company recently announced a change in corporate structure. Founders Larry Page and Sergey Brin formed Alphabet Inc, a holding company that will hold all of Google’s various businesses. Each business will be essentially treated and run independently in its own silo, but the main takeaway is that the company should now be more transparent with regards to investor reporting. Sundar Pichai was tapped to be the CEO of the Google unit.
- JD.com (JD): This stock graces this list for the second quarter in a row. The Chinese e-commerce play is a popular bet among hedge funds, especially ‘Tiger Cubs,’ or funds run by managers that previously worked at Tiger Management. During Q2, funds such as Tiger Management, Coatue, Lone Pine, and Tiger Global all boosted their exposure to the name. The thesis here is that the company has a huge total addressable market and the potential to boost margins.
- Charter Communications (CHTR): For the second consecutive quarter, CHTR lands on this list. Bridger Management, Farallon, Lone Pine, and Berkshire Hathaway were all out buying more shares. The company is set to merge with Time Warner Cable (TWC) and Bright House, pending regulatory approval. Given that part of the deal is payable in stock, arbitrageurs shorted CHTR shares to hedge their TWC long positions, driving down CHTR’s stock price and providing an opportunity for these hedge funds to increase their exposure.
- General Motors (GM):Shares of this automotive giant were bought by Omega, Glenview, Greenlight Capital, and Appaloosa Management in Q2.
- Allergan (AGN): This stock graces this list for the third quarter in a row, but in reality is more of a ‘mixed activity’ name. While a bunch of hedge funds added to their positions, a bunch of others decreased their stakes. Previously known as Actavis (ACT), the company acquired Allergan (AGN) and then reverted to using that name and ticker symbol. Maverick Capital, Lone Pine, Viking Global, and Paulson & Co were all out adding to their positions. AGN also recently sold its generic drug business to Teva Pharmaceutical (TEVA), freeing up some capital to pay down debt. Management has also hinted that they’ll look to buy other companies too.
*** Consensus Sold Positions :
- Micron (MU): Appaloosa, Perry, Tiger, and Viking Global all dumped their positions in this memory chip maker. The industry is cyclical and sometimes supply/demand imbalances show up where a shortage can quickly turn into a surplus. The long thesis has been now that the industry has consolidated down to three major players, every participant should act rationally.
- Hilton (HLT): During Q2, funds such as Coatue, JANA Partners, and Viking Global cut HLT from their portfolios altogether.
- Dollar General (DG): Farallon, Maverick Capital, and Third Point all exited shares of DG during the second quarter. Earlier this year, the company lost out on its bid for Family Dollar, which rival Dollar Tree (DLTR) acquired.
- Informatica (INFA): This company was acquired by Permira Funds and the Canada Pension Plan Investment Board. Funds such as Farallon, Hound Partners, and Tiger all closed their positions. Instead of waiting for the deal to close and capturing a small spread, they probably exited their stakes to free up capital to deploy into opportunities with more potential upside.
*** Consensus Decreased Positions :
- American International Group (AIG): As the discount to book value has narrowed, funds have slowly been cutting their exposure to AIG. Viking Global, Glenview, Blue Ridge, Hound, Omega, Perry, and Fairholme all were out selling shares. Fairholme, arguably the most notable shareholder given its highly concentrated position in AIG, actually cut its stake by over 20% during Q2. This has been yet another successful investment for many of these funds as many have owned it for several years.
- eBay (EBAY): This is the second quarter in a row that EBAY has made this list. This time around, Omega, Farallon, Glenview, and Third Point all reduced their position sizes. The company
- Transdigm Group (TDG): The theme this quarter definitely seems to be taking some profits in winning positions. This stock has been an absolute monster for years as CEO Nick Howley’s roll-up strategy has built quite the compounder. Hound, Maverick, Tiger Global, and Pennant all reduced exposure to this stock in Q2.
- Valeant Pharmaceuticals (VRX): This is yet another case of hedge funds locking in gains on some of their big winners. Like TDG above, VRX has pursued its own roll-up strategy under CEO Mike Pearson and recently closed an acquisition of Salix Pharmaceutical. Maverick, JANA, Lone Pine, and ValueAct all sold some of their position. ValueAct specifically even said that the main reason for selling their shares is risk management. As VRX’s share price increases, their position size became even larger, which forced them to sell shares to bring it back within their position size limits.
- Allergan (AGN): This is realistically more of a ‘mixed activity’ name given that a bunch of funds trimmed their stakes, but another set of funds were also out increasing their positions. In Q2, Tiger, Bridger, Coatue, Farallon, Omega, JANA, and Third Point all trimmed their stakes in AGN. The company recently sold its generics business to Teva Pharmaceutical (TEVA).